Compare AERO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERO | PHVS |
|---|---|---|
| Founded | 1934 | 2015 |
| Country | Mexico | Switzerland |
| Employees | 4084 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | AERO | PHVS |
|---|---|---|
| Price | $15.67 | $27.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $28.57 | ★ $41.80 |
| AVG Volume (30 Days) | ★ 643.8K | 186.2K |
| Earning Date | 04-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $4.10 | N/A |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $11.51 |
| 52 Week High | $23.05 | $29.85 |
| Indicator | AERO | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 54.53 |
| Support Level | $12.26 | $24.55 |
| Resistance Level | $21.58 | $28.06 |
| Average True Range (ATR) | 0.78 | 1.33 |
| MACD | 0.39 | 0.17 |
| Stochastic Oscillator | 92.57 | 60.61 |
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.